Last updated: May 17, 2026
AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride; fixed-dose combination) is being positioned as a fast-acting antidepressant option in major depressive disorder (MDD). Near-term commercial growth depends on (1) continued payer uptake and formulary retention, (2) ongoing evidence in broader patient segments and real-world settings, and (3) competitive pressure from other rapid-acting antidepressant programs. On the exclusivity and generic-readiness front, timeline and IP risk hinge on the specific Orange Book listings and any Paragraph IV challenges tied to AUVELITY’s listed patents.
What is AUVELITY’s current clinical trials status in MDD and treatment-resistant depression?
AUVELITY is approved for the treatment of MDD in adults with dosing that combines dextromethorphan with bupropion. Clinical development has historically focused on efficacy signals in adults with MDD, with emphasis on functional outcomes and earlier separation from placebo than traditional mono-therapy antidepressants.
Which AUVELITY studies matter for the next 12 to 36 months?
Key proof points that typically drive label expansion, payer contracting, and competitive positioning include:
- Replication of efficacy in larger or more diverse MDD cohorts
- Evidence in subpopulations such as partial responders to antidepressants
- Durability of effect (maintenance or relapse-prevention signals)
- Safety/tolerability in routine care settings (sleep, activation, seizure risk, drug-drug interaction management)
Are new efficacy trials underway that could expand label scope?
Commercially material trials are those likely to:
- expand indication boundaries (severity tiers, comorbidities, inadequate response definitions)
- add differentiation endpoints that payers can underwrite (time-to-response, functional improvement, symptom-metric thresholds)
Clinical trials update (information required for this topic): No trial registry dataset, sponsor announcements, or FDA label-matching metadata were provided in the prompt. Per operating constraints, a complete, accurate clinical-trials update cannot be produced without that underlying dataset.
What does AUVELITY’s market look like: size, trends, and competitive landscape in antidepressants?
The antidepressant market is mature, but the launch and growth of fast-acting products depends on conversion of patients from existing SSRIs/SNRIs and from branded alternatives. AUVELITY’s differentiation story is tied to a distinct mechanism versus standard monoamine reuptake therapies, and to the potential for earlier symptom improvement.
How does AUVELITY compete versus ketamine/esketamine, brexpiprazole augmentation, and other new antidepressants?
Competitive pressure in MDD includes:
- NMDA-pathway agents (ketamine/esketamine), where payer and clinician adoption often depends on monitoring infrastructure and administration model
- Augmentation strategies (e.g., atypical antipsychotics adjunctive approaches) that are entrenched in managed care
- Fast-acting or novel mechanisms in development or recently launched, where formulary access can be decisive
Key market drivers for AUVELITY
Commercial performance typically correlates with:
- formulary tier placement, net price, and prior authorization criteria
- persistence and adherence, since antidepressant switching patterns are high in the first 90 to 180 days
- prescriber education around contraindications and interaction risk tied to bupropion
Market analysis and projection (information required for this topic): No AUVELITY-specific sales history, unit volume, net price, payer coverage, or competitor adoption data was provided in the prompt. Per operating constraints, a quantified market model and sales forecast cannot be produced without those inputs.
When does AUVELITY lose exclusivity and what is the Orange Book status?
Exclusivity and patent expiry determine generic and authorized brand entry timing, and they drive investor and licensing valuation.
Which patents protect AUVELITY and how many are active?
A complete answer requires:
- Orange Book “drug product” listing(s) (strength and dosage form specific)
- listed patents (active ingredient, formulation, method of use)
- each patent’s expiration date and any patent term adjustments
Orange Book status (information required for this topic): No Orange Book listing table or patent identifiers were provided in the prompt. Per operating constraints, a complete and accurate exclusivity and patent-expiration summary cannot be generated.
How strong is the patent estate for AUVELITY against generics and biosimilar-like risks?
AUVELITY is a small-molecule combination product, not a biologic. “Biosimilar risk” does not apply in the same way as for biologics, but it can face generic entry risks through:
- Paragraph IV certifications
- formulation and method-of-use patent workarounds
- route and process claims (if any are listed)
What generic entry risks exist for AUVELITY?
Generic entry risk is typically a function of:
- whether the core active-ingredient patent set expires earlier than formulation and use patents
- whether there is an enforceable formulation or method-of-treatment barrier
- the presence or absence of litigation or settlement-driven “design-around” windows
Patent strength and litigation risk (information required for this topic): No patent list, lawsuit docket numbers, or settlement terms were provided in the prompt. Per operating constraints, a detailed strength assessment and risk ranking cannot be produced accurately.
What AUVELITY formulation and method-of-use patents could block alternative products?
For combination antidepressant products, blocking patents usually fall into:
- fixed-dose formulation compositions
- specific dosing regimens or patient-response-related method claims
- manufacturing/process patents for release characteristics, stability, or component ratios
Which dosage forms and strengths are covered?
A complete coverage map requires product strength-level Orange Book matching (tablet strength matters for generic “same drug” determinations).
Formulation/method-of-use coverage (information required for this topic): No Orange Book patent-to-strength mapping was provided in the prompt. Per operating constraints, a defensible claim coverage table cannot be produced.
Has AUVELITY faced Paragraph IV challenges or patent litigation, and what settlements shaped launch timing?
Generic entry risk and delay are typically driven by:
- Paragraph IV notice filings and FDA ANDA status
- district court outcomes (injunctions or non-infringement rulings)
- settlement agreements that define “launch-at” dates or design-around requirements
What litigation affects AUVELITY’s generic launch schedule?
A complete answer requires:
- case captions, court, filing date, and parties
- asserted patents (numbers)
- claim construction or final judgments
- any FDA/ANDA status outcomes tied to settlements
Litigation update (information required for this topic): No litigation dataset, court case list, or settlement terms were provided. Per operating constraints, the section cannot be completed.
What is the FDA regulatory status of AUVELITY and how do review milestones affect commercialization?
FDA status can influence payer confidence and prescriber adoption through:
- label specificity and boxed warnings or contraindications
- required REMS or postmarketing commitments (if any)
- any label updates that strengthen differentiating claims
Which FDA approvals and label updates matter?
Key items include:
- original approval date
- any supplemental indications or label expansions
- postmarketing safety updates that affect risk-management practices
FDA status update (information required for this topic): No FDA label version identifiers or supplement history were provided in the prompt. Per operating constraints, a complete status timeline cannot be produced.
AUVELITY vs. competing antidepressants: how does mechanism, onset profile, and payer access compare?
Business-relevant differentiation usually comes down to:
- time-to-response curves
- responder rates at clinically meaningful timepoints
- tolerability profiles tied to discontinuation rates
- payer access barriers (PA criteria, step edits, quantity limits)
Competitive comparison table (required data)
A usable projection needs:
- competitor net sales trajectories
- AUVELITY’s net sales and market share
- formulary coverage percentages by major PBMs
- switching and persistence curves by class
Comparison and projection (information required for this topic): No AUVELITY and competitor sales/coverage inputs were provided. Per operating constraints, a quantified comparison table and projection cannot be produced.
Sales projection for AUVELITY (2025–2030): revenue model, adoption curve, and scenario ranges
A credible forecast requires at minimum:
- historical AUVELITY prescription volume or sales by quarter
- net pricing and rebate assumptions
- formulary access and persistence/retention
- impact of patent timeline and generic entry probability
Sales projection (information required for this topic): No historical sales, net price, or adoption data were provided. Per operating constraints, a numerical forecast cannot be generated.
Key takeaways
- AUVELITY’s commercial trajectory depends on formulary access, adherence and persistence in routine care, and competitive pressure from faster-acting antidepressant strategies.
- A complete clinical trials and Orange Book-based exclusivity view cannot be produced from the prompt.
- A quantified market projection cannot be produced without AUVELITY-specific historical sales/coverage inputs and competitor adoption data.
FAQs
- What endpoints drive payer acceptance for fast-acting antidepressants like AUVELITY?
- How do bupropion-related contraindications and drug-drug interactions affect AUVELITY prescriber adoption in managed care?
- What is the typical impact of prior authorization and step-edit policies on new antidepressant brand uptake?
- What factors determine whether generics can enter a combination fixed-dose product like AUVELITY on an early FDA date?
- How should AUVELITY be benchmarked against NMDA-pathway antidepressants in real-world effectiveness models?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-18).
- FDA. Drugs@FDA. (Accessed 2026-05-18).
